carbostyril has been researched along with Cognition Disorders in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (22.22) | 29.6817 |
| 2010's | 20 (74.07) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Kamińska, K; Lech, MA; Lorenc-Koci, E; Rogóż, Z | 1 |
| Barone, FC; Hu, E; Lepore, J; Li, J; Poon, C; Qin, P; Rivera, K; Rosenbaum, DM; Willette, RN; Zhou, J; Zhuang, J | 1 |
| Cichocki, M; Jarmuszkiewicz, Z; Kus, K; Nowakowska, E; Ratajczak, P; Woźniak, A | 1 |
| Breitenbucher, JG; Gomez, L | 1 |
| Anzai, N; Furukawa, S; Hatsuse, N; Ikebuchi, E; Iwata, K; Kishimoto, T; Matsuda, Y; Sato, S; Watanabe, Y | 1 |
| Fujita, Y; Futamura, T; Hashimoto, K; Kikuchi, T; Ohgi, Y; Yoshimi, N | 1 |
| Futamura, T; Hashimoto, K; Yoshimi, N | 1 |
| Fujita, Y; Hashimoto, K; Iyo, M; Matsuura, A | 1 |
| Bubser, M; Conn, PJ; Dencker, D; Gould, RW; Grannan, M; Jones, CK; Lindsley, CW; Locuson, C; Wess, J; Xiang, Z; Zhan, X | 1 |
| Guo, H; Lai, J; Wang, Y; Yan, P; Yin, F; Zhang, J | 1 |
| Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Kane, JM; Pikalov, A; Whitehead, R | 1 |
| Schwankhaus, J; Singh, S | 1 |
| Gen, K; Inoue, Y; Suzuki, H | 1 |
| Calcagno, E; Carli, M; Invernizzi, RW; Mainini, E; Mainolfi, P | 1 |
| Danysz, W; Dekundy, A; Gravius, A; Hechenberger, M; Mela, F; Nagel, J; Parsons, CG; Pietraszek, M; Tober, C; van der Elst, M | 1 |
| Kaneda, A; Kaneko, S; Sugawara, N; Tomita, T; Yasui-Furukori, N | 1 |
| Chen, CK; Chou, MC; Chou, WJ; Huang, YS; Tang, CS; Wang, LJ; Yeh, CB | 1 |
| Hayashi, K; Hori, H; Ikenouchi-Sugita, A; Katsuki, A; Nakamura, J; Umene-Nakano, W; Yoshimura, R | 1 |
| Citraro, R; Davoli, A; De Sarro, G; Di Paola, ED; Gallelli, L; Russo, E | 1 |
| Ahn, ES; Pidcock, FS; Sanz, JH; Slomine, BS; Wachtel, LE; Yap, JL | 1 |
| Attademo, L; Moretti, P; Quartesan, R | 1 |
| Gründer, G; Gur, R; Hiemke, C; Schorn, H; Vernaleken, IB; Veselinovic, T; Zernig, G | 1 |
| Higuchi, Y; Kawasaki, Y; Miyanishi, T; Seo, T; Sumiyoshi, T; Suzuki, M | 1 |
| Alao, AO; Koss, M; Pohl, EL; Soderberg, M | 1 |
| Bies, RR; Chew, ML; Gharabawi, G; Greenspan, A; Kapur, S; Kirshner, MA; Lehman, ME; Mulsant, BH; Pollock, BG | 1 |
| Limosin, F | 1 |
| Singh Ajit, S | 1 |
4 review(s) available for carbostyril and Cognition Disorders
| Article | Year |
|---|---|
PDE2 inhibition: potential for the treatment of cognitive disorders.
Topics: Animals; Cognition Disorders; Cyclic Nucleotide Phosphodiesterases, Type 2; Humans; Ligands; Permeability; Phosphodiesterase Inhibitors; Protein Binding; Quinolones; Structure-Activity Relationship | 2013 |
The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Female; Humans; Male; Piperazines; Placebos; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2008 |
Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity.
Topics: Animals; Anticonvulsants; Antidepressive Agents; Aripiprazole; Behavior, Animal; Cognition; Cognition Disorders; Depression; Disease Models, Animal; Epilepsy, Absence; Nootropic Agents; Piperazines; Quinolones; Rats; Rats, Inbred Strains | 2013 |
[The use of atypical antipsychotics in the long-term care of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Cognition Disorders; Drug Tolerance; Dyskinesia, Drug-Induced; Haloperidol; Humans; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Sulpiride; Time Factors | 2006 |
4 trial(s) available for carbostyril and Cognition Disorders
| Article | Year |
|---|---|
Effects of risperidone and aripiprazole on neurocognitive rehabilitation for schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Drug Synergism; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Social Behavior; Young Adult | 2014 |
An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Attention; Benzodiazepines; Chronic Disease; Cognition Disorders; Dose-Response Relationship, Drug; Drug Substitution; Executive Function; Female; Humans; Isoindoles; Longitudinal Studies; Male; Memory; Middle Aged; Neuropsychological Tests; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Single-Blind Method; Thiazoles; Time Factors; Verbal Learning | 2011 |
Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chemotherapy, Adjuvant; Cognition; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Olanzapine; Piperazines; Quinolones; Receptors, Dopamine D2; Risperidone; Schizophrenia | 2012 |
Effects of antipsychotic treatment on cognition in healthy subjects.
Topics: Adrenergic Uptake Inhibitors; Adult; Antipsychotic Agents; Aripiprazole; Attention; Brain; Cognition; Cognition Disorders; Dopamine Antagonists; Female; Haloperidol; Humans; Learning; Male; Middle Aged; Neurons; Piperazines; Quinolones; Reaction Time; Reserpine; Single-Blind Method; Young Adult | 2013 |
19 other study(ies) available for carbostyril and Cognition Disorders
| Article | Year |
|---|---|
N-Acetylcysteine and Aripiprazole Improve Social Behavior and Cognition and Modulate Brain BDNF Levels in a Rat Model of Schizophrenia.
Topics: Acetylcysteine; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cognition; Cognition Disorders; Disease Models, Animal; Female; Hippocampus; Prefrontal Cortex; Pregnancy; Quinolones; Rats; Rats, Sprague-Dawley; Schizophrenia; Social Behavior | 2022 |
The prolyl 4-hydroxylase inhibitor GSK360A decreases post-stroke brain injury and sensory, motor, and cognitive behavioral deficits.
Topics: Administration, Oral; Animals; Behavior, Animal; Brain; Brain Injuries; Cognition Disorders; Erythropoietin; Glycine; Hypoxia-Inducible Factor 1, alpha Subunit; Infarction, Middle Cerebral Artery; Male; Motor Activity; Organ Specificity; Prolyl Hydroxylases; Prolyl-Hydroxylase Inhibitors; Quinolones; Rats, Sprague-Dawley; RNA, Messenger; Sensation; Stroke; Vascular Endothelial Growth Factor A | 2017 |
Influence of aripiprazole and olanzapine on behavioral dysfunctions of adolescent rats exposed to stress in perinatal period.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Cognition Disorders; Depression; Disease Models, Animal; Drug Administration Schedule; Female; Male; Maze Learning; Memory Disorders; Olanzapine; Piperazines; Pregnancy; Prenatal Exposure Delayed Effects; Quinolones; Rats; Rats, Wistar; Schizophrenia; Stress, Psychological; Time Factors | 2013 |
Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.
Topics: Animals; Cognition Disorders; Male; Mice; Mice, Inbred ICR; Phencyclidine; Quinolones; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine; Thiophenes | 2014 |
Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator.
Topics: Analysis of Variance; Animals; Cognition Disorders; Dizocilpine Maleate; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Male; Mice; Mice, Inbred C57BL; Quinolones; Recognition, Psychology; Serotonin Agents; Social Behavior; Thiophenes | 2015 |
Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Chromatography, Liquid; Cognition Disorders; D-Amino-Acid Oxidase; Drug Interactions; Excitatory Amino Acid Antagonists; Hyperkinesis; Male; Mice; Models, Animal; Motor Activity; Phencyclidine; Prepulse Inhibition; Quinolones; Receptors, N-Methyl-D-Aspartate; Serine; Sodium Benzoate | 2015 |
Role for the M1 Muscarinic Acetylcholine Receptor in Top-Down Cognitive Processing Using a Touchscreen Visual Discrimination Task in Mice.
Topics: Analysis of Variance; Animals; Cholinergic Agents; Cognition Disorders; Conditioning, Operant; Discrimination, Psychological; Dose-Response Relationship, Drug; Gene Expression Regulation; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pattern Recognition, Visual; Photic Stimulation; Quinolones; Receptor, Muscarinic M1; Reinforcement Schedule; Reinforcement, Psychology; RNA, Messenger; Touch | 2015 |
The Role of Dopamine D1 and D3 Receptors in N-Methyl-D-Aspartate (NMDA)/GlycineB Site-Regulated Complex Cognitive Behaviors following Repeated Morphine Administration.
Topics: Analgesics, Opioid; Analysis of Variance; Animals; Choice Behavior; Cognition Disorders; Cyclopentanes; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Impulsive Behavior; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Morphine; Opioid-Related Disorders; Quinolones; Reaction Time; Receptors, Dopamine D1; Receptors, Dopamine D3; Receptors, Glycine; Receptors, N-Methyl-D-Aspartate | 2017 |
Olfactory disturbance in Parkinson disease.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Biomarkers; Brain; Cognition Disorders; Constipation; Diagnosis, Differential; Disease Progression; Electroencephalography; Hallucinations; Humans; Levetiracetam; Lewy Body Disease; Male; Olfactory Pathways; Parkinson Disease; Piperazines; Piracetam; Quinolones; REM Sleep Behavior Disorder; Treatment Failure; Tremor | 2009 |
Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Choice Behavior; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Glutamic Acid; Haloperidol; Impulsive Behavior; Male; Microdialysis; Neuropsychological Tests; Olanzapine; Piperazines; Prefrontal Cortex; Quinolones; Rats; Reaction Time; Schizophrenia; Serotonin; Time Factors | 2011 |
Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Allosteric Regulation; Analysis of Variance; Animals; Brain; Calcium; Cognition Disorders; Conditioning, Psychological; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Fear; In Vitro Techniques; Levodopa; Male; Maze Learning; Microdialysis; Monoamine Oxidase Inhibitors; Motor Activity; Oxidopamine; Pain Measurement; Parkinson Disease, Secondary; Picolinic Acids; Psychomotor Performance; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Rotarod Performance Test; Tandem Mass Spectrometry; Time Factors | 2011 |
Neurocognitive effects of aripiprazole in adolescents and young adults with bipolar disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Brief Psychiatric Rating Scale; Cognition; Cognition Disorders; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Male; Piperazines; Prospective Studies; Quinolones; Severity of Illness Index; Taiwan; Young Adult | 2012 |
The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Dose-Response Relationship, Drug; Female; Humans; Japan; Male; Middle Aged; Neuropsychological Tests; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Statistics as Topic; Treatment Outcome; Young Adult | 2012 |
Treatment of cerebellar cognitive affective syndrome with aripiprazole.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Cerebellar Diseases; Cognition Disorders; Female; Humans; Infratentorial Neoplasms; Mood Disorders; Neurosurgical Procedures; Papilloma, Choroid Plexus; Piperazines; Postoperative Complications; Quinolones; Syndrome | 2012 |
[Efficacy of aripiprazole on cognitive and behavioral changes in a young woman with systemic lupus erythematosus].
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Female; Humans; Lupus Erythematosus, Systemic; Mental Disorders; Piperazines; Quinolones | 2012 |
Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Electroencephalography; Evoked Potentials; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Young Adult | 2013 |
Aripiprazole in the treatment of delirium.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Delirium; Female; Humans; Male; Neuropsychological Tests; Piperazines; Quinolones | 2005 |
A model of anticholinergic activity of atypical antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Binding Sites; Clozapine; Cognition Disorders; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Humans; Male; Neuropsychological Tests; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Receptors, Cholinergic; Risperidone; Schizophrenia; Thiazoles | 2006 |
Does aripiprazole have a role in treating cognitive impairment in Parkinson's disease?
Topics: Acetylcholine; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Drug Administration Schedule; Humans; Male; Middle Aged; Parkinson Disease; Piperazines; Quinolones; Serotonin | 2007 |